+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "B Cell Maturation Antigen"

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026 - Product Thumbnail Image

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
BCMA-targeted CAR-T Cell Therapy Market - Global Forecast 2025-2030 - Product Thumbnail Image

BCMA-targeted CAR-T Cell Therapy Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 192 Pages
  • Global
From
CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region, 2025-2035 - Product Thumbnail Image

CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region, 2025-2035

  • Report
  • January 2026
  • Global
From
CAR-T Therapy Market Report 2026 - Product Thumbnail Image

CAR-T Therapy Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
CAR T-Cell Therapy for Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Thumbnail Image

CAR T-Cell Therapy for Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • November 2025
  • 200 Pages
  • Global
From
CAR T-cell Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025 - Product Thumbnail Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 450 Pages
  • Global
From
CAR-T - Pipeline Insight, 2025 - Product Thumbnail Image

CAR-T - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
CAR T-Cell Therapy For Multiple Myeloma - Pipeline Insight, 2025 - Product Thumbnail Image

CAR T-Cell Therapy For Multiple Myeloma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Thumbnail Image

CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • November 2025
  • 182 Pages
  • Global
From
Global Cell Based Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Thumbnail Image

Global Cell Based Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • May 2025
  • 110 Pages
  • Global
From
CAR T-Cell Therapy Market Report and Forecast 2025-2034 - Product Thumbnail Image

CAR T-Cell Therapy Market Report and Forecast 2025-2034

  • Report
  • July 2025
  • 350 Pages
  • Global
From
Immunotherapy Drug for Multiple Myeloma Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Thumbnail Image

Immunotherapy Drug for Multiple Myeloma Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • November 2025
  • 150 Pages
  • Global
From
Antibody-Drug Conjugate (ADC) Market Insights, Analysis and Forecast 2026-2031 - Product Thumbnail Image

Antibody-Drug Conjugate (ADC) Market Insights, Analysis and Forecast 2026-2031

  • Report
  • February 2026
  • 133 Pages
  • Global
From
CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033 - Product Thumbnail Image

CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033

  • Report
  • June 2025
  • 180 Pages
  • Global
From
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis - Product Thumbnail Image

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

  • Report
  • July 2022
  • 263 Pages
  • Global
From
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 - Product Thumbnail Image

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026

  • Report
  • November 2021
  • 222 Pages
  • Global
From
Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), by Indication (B-cell Malignancies, Prostate Cancer), by End-use, by Region, and Segment Forecasts, 2022-2030 - Product Thumbnail Image

Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), by Indication (B-cell Malignancies, Prostate Cancer), by End-use, by Region, and Segment Forecasts, 2022-2030

  • Report
  • July 2022
  • 165 Pages
  • Global
From
CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034

  • Report
  • March 2024
  • 200 Pages
  • Global
From
Biospecific Antibody Market Analysis & Forecast to 2023-2033: Market By Drug Type; By Indication; By Distribution Channel; and by Region - Product Thumbnail Image

Biospecific Antibody Market Analysis & Forecast to 2023-2033: Market By Drug Type; By Indication; By Distribution Channel; and by Region

  • Report
  • July 2023
  • 145 Pages
  • Global
From
Loading Indicator

The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells. BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more